Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Februar 2019

Planlagt Fastgjort Låst Flyttet Genmab
3.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    peter12
    wrote on sidst redigeret af
    #991

    Godt studie for pts ! Så må man bare håbe man er på CT holdet 😉

    1 Reply Last reply
    0
    • troldmandenT Offline
      troldmandenT Offline
      troldmanden
      wrote on sidst redigeret af
      #992

      solsen lige præcis aftalerne med Jansen på duo er alt andet end end lukrative. Det er en cifrede royalties og er det $20 mio milestones perr stof. Den aftale er lavet i en tid hvor Genmab ikke stod sstærkt. En ny aftale i dag ville se signifikant meget anderledes ud

      1 Reply Last reply
      0
      • troldmandenT Offline
        troldmandenT Offline
        troldmanden
        wrote on sidst redigeret af
        #993

        jeg er også enig omkring guidens. Altså at det er "normalt" man hjælper markedet med at snævre et stort spænd ind sidst på året. Det ville være let at have indsnævret til 2-2,15 mia og så opdateret på dollar og dermed indtjening. Jeg tror udgifterne er yderligere accelerert så de selv med den stigende dollar havner tæt på kanten af nedre ranges

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #994

          Øh. Genmab will potentially be entitled to milestone and license payments of up to approximately $175 million (DKK 1,062 million) for each product as well as royalties on any commercialized products.

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #995

            NovoN: Genmab er berettiget til potentielle betalinger ved opnåelse af udviklings-, regulatoriske og salgs-milestones på op til ca. USD 250 mio. for hver eksklusive licens eller ca. USD 200 mio. for hver ikke-eksklusive licens. Endvidere vil Genmab være berettiget til encifrede royalties af salg af ethvert kommercialiseret produkt.

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #996

              Jo alle de penge i fremtiden er gode nok. Men jeg påpeger blot at nuværende opgivende stemning ikke løses af nogle udviklingsaftaler. Men aftaler på lidt mere modne stoffer med højere upfront kunne give det løft i kursen alle sukker efter. Specielt håber jeg at data på CD3/CD20 kunne fremdrive en pæn aftale. Time will show.

              1 Reply Last reply
              0
              • JørgenVarnæsJ Offline
                JørgenVarnæsJ Offline
                JørgenVarnæs
                wrote on sidst redigeret af
                #997

                Det er ved at være 3 uger siden vi fik RTOR meddelelsen - det kunne være forrygende med en af de gode gamle fredagsnyheder efter luk!!!

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #998

                  Åh nej..Den slags gjorte det så svært for mig at komme på arbejde lørdag morgen. 😄

                  1 Reply Last reply
                  0
                  • JørgenVarnæsJ Offline
                    JørgenVarnæsJ Offline
                    JørgenVarnæs
                    wrote on sidst redigeret af
                    #999

                    Du er sikker på, at det ikke var den resulterende rødvin, der skabte problemerne?

                    1 Reply Last reply
                    0
                    • T Offline
                      T Offline
                      transalp
                      wrote on sidst redigeret af
                      #1000

                      :))

                      1 Reply Last reply
                      0
                      • J Offline
                        J Offline
                        JKY_VH
                        wrote on sidst redigeret af
                        #1001

                        Det var den gang, hvor garageporten skulle beklædes med bladguld og der skulle graves ud til en stor vinkælder 😉

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #1002

                          where do you think we are on that RTOR timeline? i saw earlier in this onclive article "Janssen and Genmab have completed the first part of a supplemental biologics license application for daratumumab …." https://www.onclive.com/web-exclusives/fda-approves-splitdosing-regimen-of-daratumumab-for-multiple-myeloma?p=2

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            peter12
                            wrote on sidst redigeret af
                            #1003

                            EL later it says : The agency is reviewing the sBLA under the Real-Time Oncology Review pilot program

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              peter12
                              wrote on sidst redigeret af
                              #1004

                              BTW GMXAY is higher tonight so may some surprises around the corner

                              1 Reply Last reply
                              0
                              • nohopeN Offline
                                nohopeN Offline
                                nohope
                                wrote on sidst redigeret af
                                #1005

                                GMXAY is not a good indicator to GEN.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #1006

                                  well yeah, that is part of the sentence, the question is, where are we in the RTOR, what part of the application have they completed , are we in week 6/9 or week 16?

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #1007

                                    14-16 I belive - from top line data announcement.

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #1008

                                      All we need is announcement on last dataset submitted. And after that we need a week or so.

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #1009

                                        According to the timeline first submission takes place 6-9 weeks after top line. That was 3 weeks ago. Lets say week 12 now then. Which means another 4 weeks to last submission. And then another 4 weeks until decision. This is maximum. Could be shorter.

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #1010

                                          Could also be within 4 weeks if data are ready.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger